Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAustralian Clinical Labs Ltd

Australian Clinical Labs Ltd

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
3.24 AUD 0.04 ( 1.25%)
Last update at 2026-11-06T05:10:00Z
VOLUME
314093
Market Cap
596.86M
P/E
26.67

Momentum Score

…

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers cardiac testing, gastroenterology, haematology, chemical pathology, antenatal testing, serology and microbiology, cervical screening, commercial drug and alcohol testing, STI Testing, veterinary pathology, molecular cancer services, clinical trials pathology, advanced genetic testing, functional pathology, histopathology and cytopathology, CPD education programs for clinicians, and allergy and immunology services. It also provides workplace services, environmental screening, and clinical trial services. The company offers its services under the SunDoctors, SouthernSun Pathology, Specialised Trials, BeFunctional Labs, and Gribbles Veterinary Pathology brands. It serves doctors, patients, and corporate clients. The company was founded in 2015 and is headquartered in Clayton, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.18
Low
3.27
High
52 Week Price Range
1.77
Low
3.32
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Australian Clinical Labs Ltd provides diagnostic pathology and laboratory services across Australia and New Zealand, serving hospitals, general practitioners and community collection centres. Its long-term growth may be supported by demographic trends that increase demand for testing and by expansion opportunities that could deliver scale efficiencies and higher referral volumes.
The company faces material risks from potential changes to government reimbursement and regulation, strong competition from other national pathology providers, execution and integration risk from acquisitions, and sensitivity to testing volume swings and workforce and supply constraints.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.20
Dividend Yield
4.10%
Revenue TTM
736.15M
Revenue Per Share
3.84
Gross Profit TTM
280.68M
Debt / Equity
2.26
ROE
14.93%
Net Debt
312.67M
ROCE
16.06%
Diluted EPS TTM
0.12

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Income before tax 37.39M 48.18M 48.18M 36.37M 36.37M
Minority interest - -0.39M -0.39M -0.31M -0.31M
Net income 23.71M 32.43M 32.43M 23.93M 23.93M
Selling general administrative - 329.06M 329.06M 312.67M 312.67M
Selling and marketing expenses - - - 225.47M -225.47M
Gross profit 150.21M 270.86M 270.86M 138.45M 138.45M
Reconciled depreciation - 136.04M 136.04M 128.43M 128.43M
Ebit 61.49M 68.00M 68.00M 41.22M 41.22M
Ebitda 196.84M 81.36M 81.36M 169.65M 169.65M
Depreciation and amortization 135.35M 13.35M 13.35M 128.43M 128.43M
Operating income 61.49M 270.86M 270.86M 56.91M 56.91M
Other operating expenses 668.03M 470.41M 470.41M 633.82M 633.82M
Interest expense 18.45M 18.37M 18.37M 17.04M 17.04M
Tax provision - 15.36M 15.36M 12.12M 12.12M
Interest income - 0.41M 0.41M 0.50M 0.50M
Net interest income - -17.96M -17.96M -16.54M -16.54M
Income tax expense 13.38M 15.36M 15.36M 12.12M 12.12M
Total revenue 729.52M 741.27M 741.27M 689.73M 689.73M
Total operating expenses 88.72M 89.98M 89.98M 81.55M 81.55M
Cost of revenue 579.31M 470.41M 470.41M 551.28M 551.28M
Total other income expense net -24.10M -222.68M -222.68M -20.54M -20.54M
Net income from continuing ops - 32.82M 32.82M 24.24M 24.24M
Net income applicable to common shares - 32.43M 32.43M 23.93M 23.93M
Breakdown 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Total assets 592.66M 574.84M 574.84M 593.06M 593.06M
Intangible assets 5.86M 6.10M 6.10M 6.26M -
Other current assets 5.58M 11.99M 0.68M 8.50M 8.50M
Total liab 442.90M 402.86M 402.86M 415.30M 415.30M
Total stockholder equity 149.52M 171.35M 171.35M 177.53M 177.53M
Other current liab 84.75M 87.27M 0.46M 73.57M 73.57M
Common stock 758.94M 780.73M - 791.76M 791.76M
Capital stock - 775.52M 775.52M 791.76M -
Retained earnings 165.66M 33.75M 166.54M 159.05M 159.05M
Good will 159.11M 159.11M 159.11M 158.68M 158.68M
Other assets - 16.97M - 10.74M 0.00M
Cash 24.73M 21.44M 21.44M 26.14M 26.14M
Cash and equivalents - 21.44M - 26.14M -
Total current liabilities 209.87M 216.41M 216.41M 207.70M 207.70M
Current deferred revenue - - - - 3.24M
Net debt 312.67M 268.94M 20.53M 282.76M 282.76M
Short term debt 108.40M 108.60M - 104.71M 104.71M
Short long term debt total 337.40M 290.38M - 308.90M 308.90M
Other stockholder equity -5.22M -5.21M - 0.05M -
Property plant equipment - 270.11M - 281.70M -
Total current assets 112.93M 120.06M 120.06M 133.60M 133.60M
Short term investments 0.93M 0.68M - 0.71M 0.71M
Net receivables 67.45M 70.33M 59.28M 81.43M 81.43M
Long term debt - 41.97M 41.97M 55.06M -
Inventory 14.25M 15.62M 15.62M 16.83M 16.83M
Accounts payable 16.72M 20.54M 20.54M 26.19M 26.19M
Accumulated other comprehensive income -769.85M -637.92M - -773.29M -773.29M
Non currrent assets other 1.95M 19.45M 2.48M 2.07M 2.07M
Non current assets total 479.72M 454.77M 454.77M 459.46M 459.46M
Capital lease obligations - 248.41M 248.41M 253.84M -
Long term debt total - 181.78M - 204.19M -
Breakdown 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Investments - - -8.89M - -7.25M
Total cashflows from investing activities -9.28M -8.89M -8.89M -7.25M -7.25M
Net borrowings - -13.00M -13.00M -11.00M -11.00M
Total cash from financing activities -150.69M -178.74M -178.74M -146.14M -146.14M
Net income 23.71M 32.43M 32.43M 23.93M 23.93M
Change in cash 3.29M -4.69M -4.69M 6.18M 6.18M
Begin period cash flow 21.44M 26.14M 26.14M 19.95M 19.95M
End period cash flow 24.73M 21.44M 21.44M 26.14M 26.14M
Total cash from operating activities 163.31M 182.80M 182.80M 159.59M 159.59M
Depreciation 135.35M 136.04M 136.04M 128.43M 128.43M
Other cashflows from investing activities - 0.10M 0.10M 0.33M 0.33M
Dividends paid 24.59M 24.95M -24.95M 19.95M -19.95M
Change to inventory 1.38M 1.21M 1.21M -1.73M -1.73M
Change to account receivables 5.35M 8.32M 8.32M -7.72M -7.72M
Sale purchase of stock -23.15M -19.12M -19.12M -1.74M -1.74M
Other cashflows from financing activities -122.95M 0.00M 0.00M -113.45M -113.45M
Capital expenditures 9.58M 8.41M 8.41M 6.50M 6.50M
Change in working capital 11.96M 9.49M 9.49M 0.49M 0.49M
Stock based compensation - 3.44M 3.44M 3.06M 3.06M
Other non cash items -7.71M 1.40M 1.40M 3.68M 3.68M
Free cash flow 153.73M 174.39M 174.39M 153.09M 153.09M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ACL
Australian Clinical Labs Ltd		 0.04
1.25%		 3.24 26.67 16.84 0.81 3.95 1.24 5.12
SHL
Sonic Healthcare Ltd		 0.18
0.91%		 20.06 16.16 17.21 0.90 1.15 1.36 8.10
IDX
Integral Diagnostics Ltd		 0.01
0.58%		 1.74 28.83 15.24 0.82 0.97 1.52 9.49
HLS
Healius Ltd		 0.01
1.01%		 0.50 - 29.24 0.26 2.08 0.94 10.14
MVF
Monash Ivf Group Ltd		 -
-%		 0.74 37.00 16.21 1.07 1.17 1.79 11.73

Profile*

Australian Clinical Labs Ltd

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers cardiac testing, gastroenterology, haematology, chemical pathology, antenatal testing, serology and microbiology, cervical screening, commercial drug and alcohol testing, STI Testing, veterinary pathology, molecular cancer services, clinical trials pathology, advanced genetic testing, functional pathology, histopathology and cytopathology, CPD education programs for clinicians, and allergy and immunology services. It also provides workplace services, environmental screening, and clinical trial services. The company offers its services under the SunDoctors, SouthernSun Pathology, Specialised Trials, BeFunctional Labs, and Gribbles Veterinary Pathology brands. It serves doctors, patients, and corporate clients. The company was founded in 2015 and is headquartered in Clayton, Australia.

1868-1892 Dandenong Road, Clayton, VIC, Australia, 3168

61 1300 453 688

https://www.clinicallabs.com.au

4500

Name Title Year Born
Ms. Melinda McGrath CEO & Exec. Director NA
Mr. James Davison Chief Financial Officer NA
Mr. Anthony Friedli Chief Operating Officer NA
Mr. Sean Jackson Chief Information Officer NA
Mr. Joe Geran National Marketing Director NA
Associate Prof. Tony Landgren National Medical Director & Chief Pathologist NA
Mr. Chris Brownlow Chief Exec. Officer of New South Wales & Australian Capital Territory NA
Ms. Shae Seymour Chief Exec. Officer of Western Australia NA
Mr. Eric Swayn Chief Exec. Officer of South Australia & Northern Territory NA
Ms. Eleanor Padman B.A., FCIS Company Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…